Thermal Ablation versus Stereotactic Ablative Body Radiotherapy to Treat Unresectable Colorectal Liver Metastases: A Comparative Analysis from the Prospective Amsterdam CORE Registry
Authors:
- Sanne NieuwenhuizenSNSanne Nieuwenhuizen
- Madelon DijkstraMDMadelon Dijkstra
- Robbert S. PuijkRobbert S. Puijk
- Florentine E. F. TimmerFTFlorentine E. F. Timmer
- Irene M. NotaINIrene M. Nota
- Jip OppermanJOJip Opperman
- Bente van Den BemdBBBente van Den Bemd
- Bart GeboersBGBart Geboers
- Alette H. RuarusARAlette H. Ruarus
- Evelien A. C. SchoutenESEvelien A. C. Schouten
- Jan J. J. de VriesJVJan J. J. de Vries
- Hester J. SchefferHSHester J. Scheffer
Open Access
Abstract
Thermal ablation and stereotactic ablative radiotherapy (SABR) are techniques to eradicate colorectal liver metastases (CRLM). This study compares the safety, efficacy and long-term oncological outcomes of these treatment methods. All prospectively registered patients (AmCORE registry) treated with thermal ablation or SABR alone for unresectable CRLM between 2007 and 2020 were analyzed using multivariate Cox-proportional hazard regression. In total 199 patients were included for analysis: 144 (400 CRLM) thermal ablation; 55 (69 CRLM) SABR. SABR patients were characterized by older age (p = 0.006), extrahepatic disease at diagnosis (p = 0.004) and larger tumors (p < 0.001). Thermal ablation patients were more likely to have synchronous disease, higher clinical risk scores (p = 0.030) and higher numbers of CRLMs treated (p < 0.001). Mortality was zero and morbidity low in both groups: no serious adverse events were recorded following SABR (n = 0/55) and nine (n = 9/144 [6.3%]; all CTCAE grade 3) after thermal ablation. SABR was associated with an inferior overall survival (OS) (median OS 53.0 months vs. 27.4 months; HR = 1.29, 95% CI 1.12–1.49; p = 0.003), local tumor progression-free survival (LTPFS) per-tumor (HR = 1.24, 95% CI 1.01–1.52; p = 0.044) and local control per-patient (HR = 1.57, 95% CI 1.20–2.04; p = 0.001) and per-tumor (HR = 1.89, 95% CI 1.44–2.49; p < 0.001). In this study thermal ablation was superior to SABR with regard to OS, LTPFS and local control, albeit at the cost of a limited risk of serious adverse events. Further studies are required to assess whether the worse outcomes following SABR were the effect of true differences in ablative treatment or a result of residual confounding.Keywords
This publication has 32 references indexed in Scilit:
- Incidence and Treatment of Local Site Recurrences Following RFA of Colorectal Liver MetastasesWorld Journal of Surgery, 2013
- Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastasesActa Oncologica, 2013
- Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factorsClinical Epidemiology, 2012
- Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrenceThe American Journal of Surgery, 2010
- Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single InstitutionJournal of the American College of Surgeons, 2010
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver MetastasesJournal of Clinical Oncology, 2009
- Local Recurrence After Laparoscopic Radiofrequency Ablation of Liver Tumors: An Analysis of 1032 TumorsAnnals of Surgical Oncology, 2008
- A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancerBritish Journal of Surgery, 2006
- Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] MetastasesAnnals of Surgical Oncology, 2001